Epileptiform seizure after sertraline treatment in an adolescent experiencing obsessive-compulsive disorder and presenting a rare pharmacogenetic status [10]

Journal of Clinical Psychopharmacology

Volumn 26, Issue 6, 2006, Pages 679-681

  Baumann, Pierre ^a   Barbe, Rémy ^b   Vabre Bogdalova, Assia ^c   Garran, Encarni ^d   Crettol, Séverine ^a   Eap, Chin B ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c Service Medico Pedagogique   (Switzerland)

^d Centre Médico Psychologique Pour Enfants   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CLOMIPRAMINE; CYTOCHROME P450 2D6; CYTOCHROME P450 3A5; ESCITALOPRAM; FLUVOXAMINE; LORAZEPAM; OLANZAPINE; SERTRALINE;

ADOLESCENT; ALLELE; ANXIETY DISORDER; BEHAVIOR THERAPY; CASE REPORT; COGNITIVE THERAPY; DISEASE SEVERITY; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG MONITORING; DRUG WITHDRAWAL; FEMALE; GENETIC ANALYSIS; GENETIC POLYMORPHISM; HUMAN; LETTER; OBSESSIVE COMPULSIVE DISORDER; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; RARE DISEASE; TONIC CLONIC SEIZURE; TREATMENT RESPONSE;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG THERAPY, COMBINATION; EPILEPSY; FEMALE; GENOTYPE; HUMANS; ISOENZYMES; OBSESSIVE-COMPULSIVE DISORDER; PHARMACOGENETICS; PHENOTYPE; SEROTONIN UPTAKE INHIBITORS; SERTRALINE;

EID: 33751120406     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000239795.14202.c3     Document Type: Letter

References (26)

1. Cook EH, Wagner KD, March JS, et al. Long-term sertraline treatment of children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry. 2001;40(10):1175-1181.
2. Alderman J, Wolkow R, Chung M, et al. Sertraline treatment of children and adolescents with obsessive-compulsive disorder or depression: pharmacokinetics, tolerability, and efficacy. J Am Acad Child Adolesc Psychiatry. 1998;37(4):386-394.
3. March JS, Biederman J, Wolkow R, et al. Sertraline in children and adolescents with obsessive-compulsive disorder - a multicenter randomized controlled trial. JAMA. 1998;280(20):1752-1756.
4. The Pediatric OCD Treatment Study POTS Team. Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study POTS. Randomized controlled trial. JAMA. 2004;292:1969-1976.
5. Hamelin BA, Turgeon J, Vallée F, et al. The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin. Clin Pharmacol Ther. 1996;60:512-521.
6. Wang JH, Liu ZQ, Wang W, et al. Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19. Clin Pharmacol Ther. 2001;70:42-47.
7. Greenblatt DJ, Von Moltke LL, Harmatz JS, et al. Human cytochromes mediating sertraline biotransformation: seeking attribution. J Clin Psychopharmacol. 1999;19:489-493.
8. Kobayashi K, Ishizuka T, Shimada N, et al. Sertraline N-demethylation is catalyzed by multiple isoforms of human cytochrome P-450 in vitro. Drug Metab Dispos. 1999;27:763-766.
9. Xu ZH, Wang W, Zhao XJ, et al. Evidence for involvement of polymorphic CYP2C19 and 2C9 in the N-demethylation of sertraline in human liver microsomes. Br J Clin Pharmacol. 1999;48:416-423.
10. Obach RS, Cox LM, Tremaine LM. Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. Drug Metab Dispos. 2005;33(2):262-270.
11. Eap CB, Bouchoux G, Amey M, et al. Simultaneous determination of human plasma levels of citalopram, paroxetine, sertraline, and their metabolites by gas chromatographymass spectrometry. J Chromatogr Sci. 1998;36:365-371.
12. Crettol S, Déglon JJ, Besson J, et al. Methadone enantiomer plasma levels, CYP2B6, CYP2C19 and CYP2C9 genotypes, and response to treatment. Clin Pharmacol Ther. 2005;78:593-604.
13. Eap CB, Buclin T, Hustert E, et al. Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects. Eur J Clin Pharmacol. 2004;60(4):231-236.
14. Løvlie R, Daly AK, Molven A, et al. Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. FEBS Lett. 1996;392:30-34.
15. Schaeffeler E, Schwab M, Eichelbaum M, et al. CYP2D6 genotyping strategy based on gene copy number determination by TaqMan real-time PCR. Hum Mutat. 2003;22(6):476-485.
16. DeVane CL, Liston HL, Markowitz JS. Clinical pharmacokinetics of sertraline. Clin Pharmacokinet. 2002;41(15):1247-1266.
17. Baumann P, Hiemke C, Ulrich S, et al. The AGNP-TDMexpert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry. 2004;37: 243-265.
18. Lundmark J, Reis M, Bengtsson F. Therapeutic drug monitoring of sertraline: variability factors as displayed in a clinical setting. Ther Drug Monit. 2000;22:446-454.
19. Baumann P, Meyer JW, Amey M, et al. Dextromethorphan and mephenytoin phenotyping of patients treated with thioridazine or amitriptyline. Ther Drug Monit. 1992;14:1-8.
20. Eap CB, Buclin T, Cucchia G, et al. Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity. Eur J Clin Pharmacol. 2004;60(4):237-246.
21. Ronfeld RA, Tremaine LM, Wilner KD. Pharmacokinetics of sertraline and its N-demethyl metabolite in elderly and young male and female volunteers. Clin Pharmacokinet. 1997;12(suppl 1):23-30.
22. Axelson DA, Perel JM, Birmaher B, et al. Sertraline pharmacokinetics and dynamics in adolescents. J Am Acad Child Adolesc Psychiatry. 2002;41(9):1037-1044.
23. Montgomery SA. Antidepressants and seizures: emphasis on newer agents and clinical implications. Int J Clin Pract. 2005;59(12):1435-1440.
24. Bhana N, Foster RH, Olney R, et al. Olanzapine - an updated review of its use in the management of schizophrenia. Drugs. 2001;61(1):111-161.
25. Kirchheiner J, Klein C, Meineke I, et al. Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics. 2003;13(10):619-626.
26. Hesse LM, He P, Krishnaswamy S, et al. Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. Pharmacogenetics. 2004;14(4):225-238.